In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Clinical Topics: Diabetes and Cardiometabolic Disease, Prevention, Novel Agents

Keywords: ACCELLite, Prediabetic State, Primary Prevention, Insulin, Diabetes Mellitus, Type 2, C-Reactive Protein, Interleukin-1beta, Insulin Resistance, Glycated Hemoglobin A, Blood Glucose, Hypoglycemic Agents, Antibodies, Monoclonal, Anti-Inflammatory Agents, Thrombosis, Inflammation, Metabolic Syndrome

< Back to Listings